Phibro Animal Health Corp Dossier
|
SectorHealth Care IndustryDrug Manufacturers - Specialty & Generic Beta (adjusted)0.65 Intrinsic Value $32.37median of 6 methods · middle span $18-$39based on filings through 31 Mar 2026 Market Price $35.87Price as of 1 Oct 2026 Near fair valueIntrinsic value is 10% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $1.5B Enterprise Value $2B Shares Outstanding 41M diluted Moat Rating Wide Next Earnings Date4 Nov 2026 Last ex-dividend2 Sep 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Phibro Animal Health Corporation (PAHC) is rated Hold, reflecting stable but unexciting earnings growth and limited near-term upside. While the core Animal Health segment continues to deliver steady growth and positive free cash flow—bolstered by the successful integration of Zoetis' medicated feed additives (MFA) portfolio—the company lacks major new product catalysts. The current valuation accurately reflects PAHC's mature profile, recurring revenues, and exposure to commodity price volatility. Disciplined capital allocation supports consistent dividends, yet macroeconomic headwinds, regulatory shifts in key markets like Brazil, and intense competition from larger animal health peers constrain re-rating potential. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$35.00 Mean target$45.00 High · most bullish analyst$58.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case reflects severe regulatory headwinds, such as stricter global restrictions on medically important antibiotics (MIAs), a slower recovery in livestock economic conditions, or integration disruptions from the Zoetis portfolio, leading to margin compression. Base CaseCentral scenario The base case assumes steady execution of the Phibro Forward initiative and continued integration of the Zoetis MFA portfolio. Animal Health segment sales are expected to grow in the mid-single digits, offset by commodity volatility in the Mineral Nutrition and Performance Products segments. EPS is projected to grow in line with management's raised guidance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |